NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Many things are changing in the MHRA review process and NICE’s appraisal process and targets.

If this case is needed to be reviewed by CHM March 21 or 22, the initial corporate expectation by NWBO is that it would follow normal RFI course (60 clock off) then 70 days.

I believe they made every effort up front to make review and appraisal devoid of self-inflicted errors, and therefore have created some better case scenarios even though they are not willing to project those.

Radically, this case might go to determination without chm and RFI, or go to chm but avoid RFI before determination. Those are very slim odds, but I think the same type of upfront effort NWBO made to receive a fast deferral decision with PIP in 2022, could be the same type of effort that might see something faster than 150 + 60 running its full course, particularly when MHRA and NICE have done so much to get their own house up to speed.